| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $95M | ||
| $91M |
Buys | $5,527,296 | 3 | 18 |
Sells | $4,994,031 | 14 | 82 |
| ENRIGHT PATRICK G | director | 3 | $5.53M | 0 | $0 | $5.53M |
| Skelton Laurence Matthew | Chief Commercial Officer | 0 | $0 | 1 | $66,419 | $-66,419 |
| Brenner Robert | Chief Medical Officer | 0 | $0 | 1 | $90,307 | $-90,307 |
| Carter Jason S | Chief Legal Officer | 0 | $0 | 1 | $107,498 | $-107,498 |
| JOHNSON DAVID LEE | Chief Operating Officer | 0 | $0 | 1 | $108,276 | $-108,276 |
| Grant Sean | CHIEF FINANCIAL OFFICER | 0 | $0 | 1 | $207,778 | $-207,778 |
| Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR | 0 | $0 | 2 | $566,738 | $-566,738 |
| Turner William D. | Chief Regulatory Officer | 0 | $0 | 4 | $1.45M | $-1.45M |
| Fordyce Marshall | PRESIDENT AND CEO | 0 | $0 | 3 | $2.4M | $-2.4M |
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Over the last 12 months, insiders at Vera Therapeutics, Inc. have bought $5.53M and sold $4.99M worth of Vera Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Vera Therapeutics, Inc. have bought $19.04M and sold $16.18M worth of stock each year.
Highest buying activity among insiders over the last 12 months: ENRIGHT PATRICK G (director) — $5.53M.
The last purchase of 5,882 shares for transaction amount of $249,985 was made by ENRIGHT PATRICK G (director) on 2025‑12‑11.
| 2026-05-12 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 18,500 0.0258% | $36.74 | $679,747 | -6.43% | |
| 2026-04-14 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 22,951 0.0346% | $44.05 | $1.01M | -19.16% | |
| 2026-02-23 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 16,925 0.0241% | $41.98 | $710,578 | -6.74% | |
| 2026-02-23 | Sale | Grant Sean | CHIEF FINANCIAL OFFICER | 4,949 0.0071% | $41.98 | $207,778 | -6.74% | |
| 2026-02-23 | Sale | Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR | 3,117 0.0044% | $41.98 | $130,864 | -6.74% | |
| 2026-02-23 | Sale | Skelton Laurence Matthew | Chief Commercial Officer | 1,582 0.0023% | $41.98 | $66,419 | -6.74% | |
| 2026-02-23 | Sale | Brenner Robert | Chief Medical Officer | 2,151 0.0031% | $41.98 | $90,307 | -6.74% | |
| 2026-02-23 | Sale | JOHNSON DAVID LEE | Chief Operating Officer | 2,579 0.0037% | $41.98 | $108,276 | -6.74% | |
| 2026-02-23 | Sale | Turner William D. | Chief Regulatory Officer | 2,187 0.0031% | $41.98 | $91,819 | -6.74% | |
| 2025-12-15 | Sale | Turner William D. | Chief Regulatory Officer | 10,000 0.0159% | $50.08 | $500,767 | -16.81% | |
| 2025-12-11 | ENRIGHT PATRICK G | director | 5,882 0.0085% | $42.50 | $249,985 | -10.78% | ||
| 2025-12-08 | Sale | Turner William D. | Chief Regulatory Officer | 10,000 0.0157% | $45.31 | $453,053 | -8.13% | |
| 2025-12-03 | Sale | Turner William D. | Chief Regulatory Officer | 10,000 0.0152% | $40.00 | $400,000 | +0.93% | |
| 2025-11-21 | Sale | Carter Jason S | Chief Legal Officer | 3,864 0.0059% | $27.82 | $107,498 | +44.66% | |
| 2025-11-11 | Sale | Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR | 15,000 0.0282% | $29.06 | $435,875 | +37.29% | |
| 2025-06-24 | ENRIGHT PATRICK G | director | 40,607 0.063% | $22.35 | $907,635 | +52.08% | ||
| 2025-06-23 | ENRIGHT PATRICK G | director | 209,393 0.3165% | $20.87 | $4.37M | +58.45% | ||
| 2025-02-26 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 9,075 0.0145% | $27.65 | $250,882 | -4.50% | |
| 2025-02-21 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 10,613 0.0158% | $27.89 | $296,032 | -7.52% | |
| 2025-01-08 | Sale | Fordyce Marshall | PRESIDENT AND CEO | 17,500 0.0275% | $41.74 | $730,535 | -37.35% |
| Fordyce Marshall | PRESIDENT AND CEO | 216744 0.3019% | $7M | 0 | 28 | |
| Grant Sean | CHIEF FINANCIAL OFFICER | 114181 0.1591% | $3.69M | 4 | 2 | +48.2% |
| Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR | 64722 0.0902% | $2.09M | 2 | 5 | +91.54% |
| Skelton Laurence Matthew | Chief Commercial Officer | 64218 0.0895% | $2.07M | 0 | 1 | |
| Brenner Robert | Chief Medical Officer | 50947 0.071% | $1.65M | 0 | 1 | |
| Carter Jason S | Chief Legal Officer | 49136 0.0685% | $1.59M | 0 | 1 | |
| JOHNSON DAVID LEE | Chief Operating Officer | 45727 0.0637% | $1.48M | 0 | 1 | |
| Turner William D. | Chief Regulatory Officer | 45313 0.0631% | $1.46M | 0 | 4 | |
| ENRIGHT PATRICK G | director | 5882 0.0082% | $189,929.78 | 6 | 0 | +74.47% |
| COMMODORE CAPITAL LP | 10 percent owner | 4400000 6.1296% | $142.08M | 1 | 1 | +19.9% |
| Sofinnova Venture Partners X, L.P. | 10 percent owner | 3467156 4.8301% | $111.95M | 3 | 0 | +74.47% |
| EMSTER KURT VON | director | 2960231 4.1239% | $95.59M | 2 | 0 | +58.05% |
| Abingworth LLP | 10 percent owner | 2960231 4.1239% | $95.59M | 1 | 0 | +57.41% |
| Carlyle Group Inc. | 10 percent owner | 2960231 4.1239% | $95.59M | 0 | 1 | |
| Carlyle Genesis UK LLC | 2960231 4.1239% | $95.59M | 0 | 1 | ||
| Katabi Maha | director | 2793987 3.8923% | $90.22M | 2 | 3 | +37.14% |
| Longitude Capital Partners IV, LLC | 10 percent owner | 1714285 2.3882% | $55.35M | 3 | 0 | +74.47% |
| SEIDENBERG BETH C | director | 131553 0.1833% | $4.25M | 19 | 3 | +96.79% |
| Curley Joanne | Chief Development Officer | 26962 0.0376% | $870,602.98 | 0 | 18 | |
| Lin Celia | Chief Medical Officer | 11010 0.0153% | $355,512.90 | 0 | 1 |
$586,486,795 | 47 | 4.28% | $2.33B | |
$678,065,999 | 37 | -13.32% | $1.89B | |
Vera Therapeutics, Inc. (VERA) | $148,770,544 | 34 | 80.63% | $2.32B |
$1,603,489 | 30 | 98.90% | $1.9B | |
$24,808,021 | 22 | 23.51% | $2.04B | |
$135,656,796 | 20 | 30.67% | $2.17B | |
$137,146,941 | 17 | 25.48% | $2.66B | |
$18,336,420 | 12 | 24.03% | $2.35B | |
$2,314,489 | 11 | -0.78% | $2.35B | |
$94,976,497 | 10 | -10.72% | $1.87B | |
$45,445,266 | 9 | -24.96% | $2.49B | |
$32,575,266 | 8 | 37.03% | $2.55B | |
$25,073,947 | 7 | -5.99% | $1.86B | |
$4,623,072 | 7 | 11.07% | $2.16B | |
$666,380 | 5 | -16.60% | $1.87B | |
$3,200,000 | 5 | -11.36% | $2.37B | |
$1,407,368 | 5 | 31.21% | $2.25B | |
$24,000,085 | 4 | 33.26% | $2.56B | |
$5,000,000 | 1 | -22.84% | $2.7B |
| Increased Positions | 149 | +87.65% | 18M | +28.31% |
| Decreased Positions | 79 | -46.47% | 9M | -14.21% |
| New Positions | 69 | New | 9M | New |
| Sold Out Positions | 21 | Sold Out | 4M | Sold Out |
| Total Postitions | 240 | +41.18% | 74M | +14.1% |
| Avoro Capital Advisors Llc | $301,930.00 | 8.87% | 6.21M | -90,000 | -1.43% | 2025-09-30 |
| Blackrock, Inc. | $206,498.00 | 6.07% | 4.25M | +81,650 | +1.96% | 2025-09-30 |
| Kynam Capital Management, Lp | $195,832.00 | 5.75% | 4.03M | +600,913 | +17.54% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $178,262.00 | 5.24% | 3.67M | -813,278 | -18.16% | 2025-09-30 |
| Deerfield Management Company, L.P. | $177,033.00 | 5.2% | 3.64M | +293,040 | +8.75% | 2025-09-30 |
| Vanguard Group Inc | $155,130.00 | 4.56% | 3.19M | +189,545 | +6.32% | 2025-09-30 |
| Fmr Llc | $138,233.00 | 4.06% | 2.84M | -66,833 | -2.3% | 2025-09-30 |
| Eversept Partners, Lp | $136,517.00 | 4.01% | 2.81M | +424,781 | +17.82% | 2025-09-30 |
| Sofinnova Investments, Inc. | $135,844.00 | 3.99% | 2.79M | 0 | 0% | 2025-09-30 |
| State Street Corp | $113,459.00 | 3.33% | 2.33M | +315,900 | +15.66% | 2025-09-30 |